355 related articles for article (PubMed ID: 26673352)
1. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S
Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352
[TBL] [Abstract][Full Text] [Related]
2. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
[TBL] [Abstract][Full Text] [Related]
4. [First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced or metastatic urothelial cell carcinoma (JASINT-1 - AB 38/11) of AUO].
Rexer H
Urologe A; 2011 Aug; 50(8):974-6. PubMed ID: 21779884
[No Abstract] [Full Text] [Related]
5. Re: Vinflunine-gemcitabine Versus Vinflunine-carboplatin as First-line Chemotherapy in Cisplatin-unfit Patients with Advanced Urothelial Carcinoma: Results of an International Randomized Phase II Trial (JASINT1).
Gakis G
Eur Urol; 2016 Aug; 70(2):399-400. PubMed ID: 27353965
[No Abstract] [Full Text] [Related]
6. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
Bamias A; Moulopoulos LA; Koutras A; Aravantinos G; Fountzilas G; Pectasides D; Kastritis E; Gika D; Skarlos D; Linardou H; Kalofonos HP; Dimopoulos MA
Cancer; 2006 Jan; 106(2):297-303. PubMed ID: 16342065
[TBL] [Abstract][Full Text] [Related]
7. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
[TBL] [Abstract][Full Text] [Related]
9. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
An X; Xue C; Chen M; Ni M; Ma H; Tian L; Huang R; Li X; Ye Y; Qin T; Dong P; Li Z; Peng J; Yao K; Zhou F; Liu Z; Shi Y
BJU Int; 2024 Jul; 134(1):63-71. PubMed ID: 38009394
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
Tan EH; Szczesna A; Krzakowski M; Macha HN; Gatzemeier U; Mattson K; Wernli M; Reiterer P; Hui R; Pawel JV; Bertetto O; Pouget JC; Burillon JP; Parlier Y; Abratt R;
Lung Cancer; 2005 Aug; 49(2):233-40. PubMed ID: 16022917
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
17. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
18. Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.
Park JH; Lee SW; Kim HS; Kang SG; Ko YH; Kim ST; Kang SH; Park YJ; Choi IK; Oh SC; Sung DJ; Seo JH; Cheon J; Kim YH; Kim JS; Park KH
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1033-9. PubMed ID: 23370665
[TBL] [Abstract][Full Text] [Related]
19. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Huang J; Su R; Chen Z; Jiang S; Chen M; Yuan Y; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Li C; Wang Z; Bao Y; Cai M; Guo J; Wei Q; Xue W
Oncoimmunology; 2022; 11(1):2124691. PubMed ID: 36148322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
